卡培他滨联合奥沙利铂对晚期结直肠癌患者血清肿瘤标志物水平的影响

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the influence of Capecitabine and Oxaliplatin on serum tumor marker levels in patients with advanced colorectal cancer.Methods A total of 85 patients with advanced colorectal cancer treated in our hospital from June2017 to May 2019 wereselected and divided intotheobservation group(43 cases)and thecontrol group(42 cases)according to the random number table method.The control group received Fluorouracil and Oxaliplatin treatment,and the observation group received Oxaliplatin and Capecitabine treatment.The clinical efficacy,serum tumor marker levels,immune function and adverse reactions were compared between the two groups.Results The clinical response rate in the observation group was 67.44%,which was higher than that in the control group(42.86%),the difference was statistically significant(P＜0.05).The level of CA125([43.09±5.63]μg/ml)and CA199([67.39±7.42]μg/ml)in the observation group after chemotherapy were lower than those in the control group ([58.61±4.81]μg/ml,[83.75±9.58]μg/ml),the level of CD4+([36.79±4.53]%),CD4+/CD8+([1.32±0.43])in the observation group after chemotherapy were higher than those in the control group([31.24±4.85]%,[1.11±0.39]),the differences were statistically significant(P＜0.05).There was no significant difference in the level of CD8+between the two groups before and after chemotherapy(P＞0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of Capecitabine and Oxaliplatin in the treatment of advanced colorectal cancer can improve the short-term efficacy,improve the immune function of patients,adjust the level of serum tumor markers,and have fewer adverse reactions.It is an effective and relatively safe chemotherapy in the treatment of advanced colorectal cancer.

Received: 19 March 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZOU Yu-bin YANGLing XIAOChi-jin CHEN Kai

Cite this article:

ZOU Yu-bin YANGLing XIAOChi-jin CHEN Kai. Advanced colorectal cancer;Capecitabine;Oxaliplatin;Serum tumor markers;Immune function[J]. 中国当代医药, 2020, 27(24): 124-126转130.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I24/124

[1]	周翡，张海燕，王静珏，等.伊立替康化疗方案联合高频热疗治疗晚期结直肠癌的临床研究[J].安徽医药，2018，22（3）：470-474.
[2]	马守东，房丽，李海丽，等.含卡培他滨双周化疗方案一线治疗晚期大肠癌临床疗效观察[J].中国煤炭工业医学杂志，2019，22（2）：129-132.
[3]	胡佳楠.卡培他滨节拍化疗在晚期结直肠癌维持治疗中的疗效观察[J].肿瘤学杂志，2019，25（6）：587-590.
[4]	马天飞，唐域.奥沙利铂联合替吉奥治疗晚期结直肠癌的临床效果[J].中国医药导报，2018，15（17）：94-97.
[5]	王鹏，何慧明.雷替曲塞联合奥沙利铂治疗晚期结直肠癌疗效及对生活质量的影响[J].山西医药杂志，2017，46（24）：3044-3046.
[6]	王红兵，蒲志忠，邓彬，等.奥沙利铂联合卡培他滨治疗晚期结直肠癌的疗效及对患者生活质量的影响[J].中国医院用药评价与分析，2018，18（5）：605-607.
[7]	闻杨，董洪敏，王文玲，等.重组人血管内皮抑制素联合化疗对晚期结直肠癌的疗效[J].中国现代医学杂志，2018，28（30）：109-114.
[8]	王皇建，韩保卫，王云帅，等.术前外周血中性粒细胞/淋巴细胞比值在结直肠癌预后中的意义[J].中国当代医药，2019，26（12）：16-19.
[9]	张伟鹏，徐元元，刘苇，等.FOLFOXIRI与SOX化疗方案治疗晚期结直肠癌的近期效果比较[J].肿瘤研究与临床，2018，30（8）：548-552.
[10]	苏正曙，陈建望，孙余挺.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的临床分析[J].实用肿瘤杂志，2017，32（1）：77-79.
[11]	李安民，盛蓉，辛建锋.奥沙利铂联合替吉奥治疗晚期结直肠癌的疗效观察[J].药物评价研究，2017，40（3）：385-388.
[12]	马玉洁，孙永琨，陈冬娜，等.伊立替康联合卡培他滨或替吉奥二线治疗晚期结直肠癌效果观察[J].肿瘤研究与临床，2019，31（6）：405-408.
[13]	殷瑛.卡培他滨联合奥沙利铂治疗不同病理类型结直肠癌的疗效观察[J].安徽医药，2019，23（10）：2078-2081.
[14]	贾珍，罗梦琳.参麦注射液对结直肠癌化疗患者免疫功能的影响[J].武警医学，2019，30（3）：221-223，227.
[15]	刘永平.卡培他滨联合奥沙利铂治疗Ⅲ期结直肠癌疗效及对患者免疫功能、生活质量的影响[J].中国基层医药，2017，24（17）：2566-2569.
[16]	李东言，杜斌，郑燕君，等.结肠癌经肠镜诊断及病理结果与CEA、CA199水平的相关性分析[J].中国实验诊断学，2018，22（10）：1744-1746.